These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
148 related articles for article (PubMed ID: 26118565)
21. Digital rectal examination is no longer necessary in the routine follow-up of men with undetectable prostate specific antigen after radical prostatectomy: the implications for follow-up. Chaplin BJ; Wildhagen MF; Schroder FH; Kirkels WJ; Bangma CH Eur Urol; 2005 Dec; 48(6):906-10. PubMed ID: 16126322 [TBL] [Abstract][Full Text] [Related]
22. Serum PSA after anatomic radical prostatectomy. The Johns Hopkins experience after 10 years. Partin AW; Pound CR; Clemens JQ; Epstein JI; Walsh PC Urol Clin North Am; 1993 Nov; 20(4):713-25. PubMed ID: 7505980 [TBL] [Abstract][Full Text] [Related]
23. Early versus delayed hormonal therapy for prostate specific antigen only recurrence of prostate cancer after radical prostatectomy. Moul JW; Wu H; Sun L; McLeod DG; Amling C; Donahue T; Kusuda L; Sexton W; O'Reilly K; Hernandez J; Chung A; Soderdahl D J Urol; 2004 Mar; 171(3):1141-7. PubMed ID: 14767288 [TBL] [Abstract][Full Text] [Related]
24. Rising prostate-specific antigen after primary treatment of prostate cancer: sequential hormone manipulation. Schmid HP; Keuler FU; Altwein JE Urol Int; 2007; 79(2):95-104. PubMed ID: 17851276 [TBL] [Abstract][Full Text] [Related]
25. The long-term clinical impact of biochemical recurrence of prostate cancer 5 or more years after radical prostatectomy. Ward JF; Blute ML; Slezak J; Bergstralh EJ; Zincke H J Urol; 2003 Nov; 170(5):1872-6. PubMed ID: 14532796 [TBL] [Abstract][Full Text] [Related]
26. [PSA and follow-up after treatment of prostate cancer]. Benchikh El Fegoun A; Villers A; Moreau JL; Richaud P; Rebillard X; Beuzeboc P Prog Urol; 2008 Mar; 18(3):137-44. PubMed ID: 18472065 [TBL] [Abstract][Full Text] [Related]
27. [PSA recurrence after primary curative therapy--local or systemic? When is a second curative therapy still possible?]. Wirth MP; Engelhardt FM Urologe A; 2005 Sep; 44(9):997-1004, 1006-7. PubMed ID: 16133232 [TBL] [Abstract][Full Text] [Related]
28. Hormonal therapy options for biochemical recurrence of prostate cancer after local therapy. Moul JW Mol Urol; 2000; 4(3):267-71;discussion 273. PubMed ID: 11062383 [TBL] [Abstract][Full Text] [Related]
29. Evaluation of the prostate bed for local recurrence after radical prostatectomy using endorectal magnetic resonance imaging. Liauw SL; Pitroda SP; Eggener SE; Stadler WM; Pelizzari CA; Vannier MW; Oto A Int J Radiat Oncol Biol Phys; 2013 Feb; 85(2):378-84. PubMed ID: 22717242 [TBL] [Abstract][Full Text] [Related]
30. Digital rectal examination and imaging studies are unnecessary in men with undetectable prostate specific antigen following radical prostatectomy. Pound CR; Christens-Barry OW; Gurganus RT; Partin AW; Walsh PC J Urol; 1999 Oct; 162(4):1337-40. PubMed ID: 10492192 [TBL] [Abstract][Full Text] [Related]
31. Rising PSA after local therapy failure: immediate vs deferred treatment. Moul JW Oncology (Williston Park); 1999 Jul; 13(7):985-90, 993; discussion 993-5, 999. PubMed ID: 10442345 [TBL] [Abstract][Full Text] [Related]
32. Management of biochemically recurrent prostate cancer following local therapy. Kolodziej M Am J Manag Care; 2014 Dec; 20(12 Suppl):S273-81. PubMed ID: 25734963 [TBL] [Abstract][Full Text] [Related]
34. Time to an undetectable prostate-specific antigen (PSA) after androgen suppression therapy for postoperative or postradiation PSA recurrence and prostate cancer-specific mortality. D'Amico AV; McLeod DG; Carroll PR; Cullen J; Chen MH Cancer; 2007 Apr; 109(7):1290-5. PubMed ID: 17315162 [TBL] [Abstract][Full Text] [Related]
35. Early salvage radiation therapy combined with short-term hormonal therapy in recurrent prostate cancer after radical prostatectomy: single-institution 4-year data on outcome, toxicity, health-related quality of life and co-morbidities from 184 consecutive patients treated with 70 Gy. Cortés-González JR; Castellanos E; Sandberg K; Eriksson MH; Wiklund P; Carlsson S; Cohn-Cedermark G; Harmenberg U; Gustafsson O; Levitt SH; Lennernäs B; Brandberg Y; Márquez M; Kälkner KM; Nilsson S Int J Oncol; 2013 Jan; 42(1):109-17. PubMed ID: 23151842 [TBL] [Abstract][Full Text] [Related]
36. Celecoxib versus placebo for men with prostate cancer and a rising serum prostate-specific antigen after radical prostatectomy and/or radiation therapy. Smith MR; Manola J; Kaufman DS; Oh WK; Bubley GJ; Kantoff PW J Clin Oncol; 2006 Jun; 24(18):2723-8. PubMed ID: 16782912 [TBL] [Abstract][Full Text] [Related]
37. Treatment of PSA only recurrence of prostate cancer after prior local therapy. Moul JW Curr Pharm Des; 2006; 12(7):785-98. PubMed ID: 16515495 [TBL] [Abstract][Full Text] [Related]
38. Prostate-specific antigen doubling times in patients who have failed radical prostatectomy: correlation with histologic characteristics of the primary cancer. Pruthi RS; Johnstone I; Tu IP; Stamey TA Urology; 1997 May; 49(5):737-42. PubMed ID: 9145980 [TBL] [Abstract][Full Text] [Related]
39. Diagnostic evaluation of PSA recurrence and review of hormonal management after radical prostatectomy. Van Poppel H; Joniau S; Van Cleynenbreugel B; Mottaghy FM; Oyen R Prostate Cancer Prostatic Dis; 2009; 12(2):116-23. PubMed ID: 19238169 [TBL] [Abstract][Full Text] [Related]
40. MR imaging evaluation with a transrectal surface coil of local recurrence of prostatic cancer in men who have undergone radical prostatectomy. Silverman JM; Krebs TL AJR Am J Roentgenol; 1997 Feb; 168(2):379-85. PubMed ID: 9016212 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]